Similar articles

• Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.

  Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H. Bar-Or A, et al. Arch Neurol. 2007 Oct;64(10):1407-15. doi: 10.1001/archneur.64.10.nct70002. Epub 2007 Aug 13. Arch Neurol. 2007. PMID: 17698695 Clinical Trial.
• Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis.

  Hellings N, Stinissen P. Hellings N, et al. Curr Opin Investig Drugs. 2008 May;9(5):534-40. Curr Opin Investig Drugs. 2008. PMID: 18465664 Review.
• T-cell vaccination in multiple sclerosis: immunoregulatory mechanism and prospects for therapy.

  Zhang J. Zhang J. Crit Rev Immunol. 2001;21(1-3):41-55. Crit Rev Immunol. 2001. PMID: 11642613 Review.
• T-cell vaccination in multiple sclerosis.

  Achiron A, Mandel M. Achiron A, et al. Autoimmun Rev. 2004 Jan;3(1):25-32. doi: 10.1016/S1568-9972(03)00060-0. Autoimmun Rev. 2004. PMID: 14871646 Review.
• DNA-based vaccines: the future of multiple sclerosis therapy?

  Stüve O, Cravens PD, Eagar TN. Stüve O, et al. Expert Rev Neurother. 2008 Mar;8(3):351-60. doi: 10.1586/14737175.8.3.351. Expert Rev Neurother. 2008. PMID: 18345967 Review.